TGen tackles diabetic blindness with new collaboration
September 25, 2018
| by City of Hope
Known as diabetic retinopathy, this disease is one of the nation’s leading causes of blindness, afflicting as many as 24,000 Americans each year. Nearly two of every five patients with diabetes also develop diabetic retinopathy.
TGen and UNM will lead a consortium that includes Harvard University’s Joslin Diabetes Center and NIH’s National Eye Institute.
Because diabetic retinopathy can affect patients in so many varying ways, the study will focus on possible genetic causes of this disease, which could potentially lead to precision medicine-based treatments that would help thousands preserve their sight.
“We hope our findings will result in a diagnostic for early prediction of disease severity, development of new biomarkers and improved therapeutic targets that may prevent the progression of diabetic retinopathy,” said Sampath Rangasamy, Ph.D., research assistant professor in TGen’s Neurogenomics Division and the study’s principal investigator.
Rangasamy — a type 1 diabetic for more than 30 years — is an expert in diabetic blindness who formerly worked at UNM under Arup Das, M.D., Ph.D., Regents’ Professor and chief of ophthalmology at the UNM School of Medicine and the study’s principal investigator.
“Our scientists are engaged in understanding the molecular mechanisms of prevalent diseases like diabetic retinopathy,” said Das, a pioneer in this area of study, who specializes in the restoration of vision in these patients at the UNM Eye Clinic. “We aim to make new discoveries that will translate into new and more effective therapies for patients.”
The study includes three crucial objectives:
The study will place an emphasis on Native American and Hispanic patients who are at higher risk of developing diabetes and diabetic retinopathy. A key question the study will address is why some patients respond well to current Food and Drug Administration-approved anti-VEGF therapy and others do not.
“Our goal is to understand the great genetic variability of this disease, and to establish a molecular profile that can predict the severity and treatment of this disease for each patient,” said Jeffrey Trent
, TGen president and research director, and also a study co-investigator.
City of Hope has a long and impressive history of groundbreaking discoveries in the field of diabetes. Arthur D. Riggs, Ph.D.
, the Samuel Rahbar Chair in Diabetes & Drug Discovery and director of the Diabetes & Metabolism Research Institute
at City of Hope, renowned for his work on synthesizing the first man-made gene and using synthetic genes to produce human insulin, said this grant is urgently needed.
“Diabetic retinopathy, with loss of vision, is a serious, common and debilitating problem associated with the complications of diabetes,” Riggs said. “This study is an exciting approach to understanding the molecular and genetic mechanisms involved, and it makes use of the extraordinary technology and expertise available at TGen and City of Hope.”
Underscoring the urgency of the study is the fact that worldwide, the number of patients with diabetes is expected to grow by more than half in the next two decades: from about 415 million today to an estimated 642 million by 2040. The annual economic impact of diabetic retinopathy in the U.S. alone is estimated at nearly $500 million.
City of Hope joined forces with TGen in 2016 to accelerate the speed with which scientists and medical staff convert research discoveries into cures for patients. The alliance is based on a simple premise: City of Hope provides a state-of-the-art clinical setting in which to advance genomic breakthroughs made by TGen.
You may also be interested in